CURETIS (ASX: CURE) - ADVANCING MOLECULAR MICROBIOLOGY

CORPORATE PRESENTATION

October 2019
DISCLAIMER & FORWARD LOOKING STATEMENTS

This document has been issued by Curetis N.V. (the “Company” and, together with its subsidiaries, the “Group”) and does not constitute or form part of and should not be construed as any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision, nor does it constitute a recommendation regarding the securities of the Company or any present or future member of the Group.

In particular, this document is not an offer of securities for sale in the United States of America. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Neither this document nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions or distributed, directly or indirectly, in the United States of America, its territories or possessions.

All information contained herein has been carefully prepared. However, no reliance may be placed for any purposes whatsoever on the information contained in this document or on its completeness. No representation or warranty, express or implied, is given by or on behalf of the Company or any of its directors, officers or employees or any other person as to the accuracy or completeness of the information or opinions contained in this document and no liability whatsoever is accepted by the Company or any of its directors, officers or employees nor any other person for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

Where third-party information has been used in this document, the source of this information has been identified. The information in this document that has been sourced from third parties has been accurately reproduced and, as far as the Company is aware and able to ascertain from the information published by that third party, the reproduced information is correct. However, the Company has not verified the reproduced information and does not guarantee nor bear or assume responsibility for the accuracy and completeness of the information from third-party sources presented in this document.

The information contained in this presentation is subject to amendment, revision and updating. Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company’s or, as appropriate, senior management’s current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any information contained in this presentation (including forward-looking statements), whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak only as of the date of this document.

By attending, reviewing or consulting the presentation to which this document relates or by accepting this document you will be taken to have represented, warranted and undertaken that you have read and agree to comply with the contents of this notice.

© 2019 Curetis N.V.
CURETIS & OPGEN TO COMBINE BUSINESSES

ESTABLISH A WORLD-LEADING ANTIMICROBIAL RESISTANCE (AMR) PRECISION MEDICINE BUSINESS

Strategic Rationale
• Establish a world-leading antimicrobial resistance (AMR) precision medicine business
• Broad portfolio of high impact rapid diagnostics and best-in-class AMR bioinformatics
• Leverage combined sales, distribution, bioinformatics and operating infrastructure

Structure of Transaction
• OpGen acquisition of Curetis GmbH for 2.66 million new shares of OpGen common stock, which corresponds to a 72.5% (CURE) to 27.5% (OPGN) relative ownership prior to any additional financing

Financial Considerations
• Combined company positioned for strong growth profile and sustained value creation
• Estimated 2020 combined revenue of $10-15 million, up from an anticipated $5-6 million in 2019
• Target to significantly reduce net loss starting in 2020 and beyond

Subject to approval by OpGen’s and Curetis’ respective regulators, shareholders, and debt financing providers
• Both companies’ Boards of Directors have approved the definitive implementation agreement
• Both companies will seek approval from their respective shareholders in extraordinary general meetings to be scheduled as soon as practicable
• Provided shareholders and debt holders for both OpGen and Curetis grant approval, the business combination is likely to be completed in early 2020 – closing is subject to successful closing of additional OPGN financing, which will be dilutive to both companies’ shareholders

Companies will pursue their normal course of business until closure of the transaction

For more information, please see: www.curetis.com/investors

© 2019 Curetis N.V.
CONTINUE TO EXECUTE ON REVISED STRATEGY

FOCUS ON NEAR-TERM STRATEGIC VALUE DRIVERS AND PARTNERING

- Entered into definitive agreement with OpGen to combine businesses
- Retained HC Wainwright to advise on strategic options and financing
- Signed R&D & Option agreement with undisclosed global IVD Player for Ares Genetics
- Signed New Distribution Agreement covering four CEE markets with AKO MED
- Submitted to FDA for 510(k) clearance of Unyvero LRT in BAL specimen
- Met with expert panel and Chinese National Medical Products Administration (NMPA) to discuss Unyvero HPN submission status
- Received additional EUR 6.5 million financing from EIB and Yorkville
- Entered broad strategic partnership with Menarini Diagnostics for pan-European distribution of Unyvero A50 product line
- Driving strategic partnering discussions for Unyvero A30 RQ platform in development with global and regional IVD players
- Continued implementation of Ares Genetics' business with Sandoz, Qiagen and introducing NGS lab services mid year.
CURETIS’ VISION

MOLECULAR MICROBIOLOGY LEADERSHIP THROUGH PROPRIETARY PLATFORMS AND CONTENT

Striving for Molecular Microbiology Leadership

<table>
<thead>
<tr>
<th>MDx Platforms</th>
<th>MDx Content</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.jpg" alt="Unyvero A50" /> High-Plex PCR</td>
<td><img src="image2.jpg" alt="ARESdb" /> MDx Content &amp; NGS Applications</td>
</tr>
<tr>
<td><img src="image3.jpg" alt="Unyvero A30 RQ" /> Low- to Mid-Plex PCR</td>
<td></td>
</tr>
</tbody>
</table>

Low- to High-Plex PCR - Broadest Sample Range

Antibiotic Resistance Data Intelligence

* Unyvero A30 RQ Analyzer in development, latest design concept; final product may differ

© 2019 Curetis N.V.
CURETIS AT A GLANCE

A COMMERCIAL STAGE MOLECULAR DIAGNOSTICS COMPANY

- Molecular Diagnostics Company with Focus on Severe Infections
- Publicly Listed on Euronext Amsterdam and Brussels
- Proprietary Unyvero Platform & AMR Content
- Commercial with CE-IVD and U.S.-FDA-cleared Unyvero Products
- Growing Global Presence
- Attractive R&D Pipeline
- Multiple Strategic Partnerships & Partnering Opportunities
IMPROVING CLINICAL PRACTICE IN MICROBIOLOGY

UNYVERO PROVIDES RAPID AND ACTIONABLE INFORMATION

Microbiology Culture

Pathogen ID: 24-48h

Antibiotic Susceptibility: 48-72h +

Unyvero

Pathogen ID & AMR Markers

4-5 h

> Fast
> Highly automated, easy-to-use
> PCR - no culture bias
> Find additional pathogens and multi-infections

Informed Therapy

Potential

Time to informed therapy
Length of stay
Mortality
Total costs per case
Antibiotic Stewardship

© 2019 Curetis N.V.
UNYVERO IN A NUTSHELL

RAPID INFECTIOUS DISEASE TESTING FOR HOSPITALIZED PATIENTS

- FAST
- COMPREHENSIVE PANELS
- FLEXIBLE ON SAMPLE TYPES
- EASY TO USE

IMPROVE CLINICAL OUTCOMES - SUPPORT ANTIBIOTIC STEWARDSHIP - CREATE HEALTHECONOMIC BENEFITS

* In development, latest design concept; final product may differ
THE UNYVERO ADVANTAGE IN SYNDROMIC TESTING

FOCUS ON MULTIPLEXING AND SAMPLE FLEXIBILITY

* In development, latest design concept; final product may differ
# BROAD CARTRIDGE PORTFOLIO

**SIX DISEASE-SPECIFIC CARTRIDGES WITH SYNDROMIC PANELS**

<table>
<thead>
<tr>
<th>Cartridge</th>
<th>Indication area</th>
<th>Number of targets*</th>
<th>Sample types</th>
<th>Clearance status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HPN</strong></td>
<td>Severe cases of Pneumonia</td>
<td>48 targets****, pathogens (29) and antibiotic resistance markers (19)</td>
<td>Sputum, broncho-alveolar lavage, tracheal aspirate</td>
<td>CE-IVD marked Singapore (HAS) Thailand Malaysia</td>
</tr>
<tr>
<td>LRT</td>
<td>Lower Respiratory Tract Infections</td>
<td>46 targets****, pathogens (36) and antibiotic resistance markers (10)</td>
<td>Tracheal aspirates LRT Application for BAL under FDA review</td>
<td>U.S. FDA cleared</td>
</tr>
<tr>
<td><strong>ITI</strong></td>
<td>Severe cases of Implant and Tissue Infections</td>
<td>102 targets, pathogens (85) and antibiotic resistance markers (17)</td>
<td>Sonication fluid, swabs, stiche, tissue, pus, aspirate/exudate, etc.</td>
<td>CE-IVD marked</td>
</tr>
<tr>
<td><strong>BCU</strong>*</td>
<td>Bloodstream infections</td>
<td>103 targets, pathogens (86) and antibiotic resistance markers (17)</td>
<td>Positively flagged blood cultures</td>
<td>CE-IVD marked Singapore (HAS) Thailand</td>
</tr>
<tr>
<td><strong>IAI</strong></td>
<td>Severe Intra-Abdominal Infections</td>
<td>130 targets, pathogens (105), toxins (3) and antibiotic resistance markers (22)</td>
<td>Paracentesis fluids, biliary fluids, peritoneal fluids, drainage fluids, retroperitoneal fluids, pus, swabs, samples from positively flagged blood culture bottles inoculated with other fluids than blood (IAI fluids such as ascites)</td>
<td>CE-IVD marked</td>
</tr>
<tr>
<td><strong>UTI</strong></td>
<td>Severe cases of Urinary Tract Infections</td>
<td>103 targets, pathogens (88) and antibiotic resistance markers (15)</td>
<td>Midstream urine, suprapubic aspiration, tissue</td>
<td>CE-IVD marked</td>
</tr>
</tbody>
</table>

*As of 31 July 2018 **HPN: Hospitalized Pneumonia ***BCU: Blood Culture Application ****Difference between HPN and LRT due to different reporting requirements between CE-IVD and U.S. FDA-cleared products
The current Unyvero portfolio and pipeline of cartridges target over 9 million patients annually in EU and U.S. with additional upside in Asia
Combination of Direct Sales & Distribution Partners

Expanding Global Commercial Reach

- Direct sales in the U.S.
- Switched key EU markets from direct sales to distribution model
- 18 distribution partners covering 43 countries in EU, ME, and Asia
- Continuously expanding partner network
PAN-EUROPEAN DISTRIBUTION BY MENARINI DIAGNOSTICS

STARTING WITH 11 EU COUNTRIES – OPTION TO EXPAND PARTNERSHIP TO FURTHER MARKETS

Menarini Diagnostics Partnership

- Covers entire Unyvero A50 product line
- Initial countries: BE, CH, DE, ES, FR, IT, LU, NL, PT, SE, UK
- Option to expand partnership to further countries
- Launched partnership at ECCMID 2019
- Customer hand-over completed in Q2-2019
CURETIS’ BUSINESS MODEL

INSTRUMENT PLACEMENTS AND CARTRIDGE UTILIZATION DRIVE SALES

“Razor / Razor-Blade“
Business Model

> Systems placed under reagent-rental / rent-to-own in direct sales markets
> ~ EUR 40,000 investment per installed system to be recouped by cartridge sales over time
> Target customers using between 200-600 cartridges per year
> Customers utilizing growing menu of cartridges over time
> 1-2 cartridges/day translate to approx. EUR 30,000-75,000 recurring revenue potential per end-customer per year

*Diagnosis-Related Groups

Microbiology Lab
- 24/7 day operation
- Minimal hands-on-time
- Workflow efficiency

ICU & Clinicians
- Fast, actionable results
- Point of need
- Antibiotic stewardship

Finance & Admin
- Improved health economics
- Increase margins on DRGs*
- Improve patient throughput

Hospital Stakeholder Benefits
CARTRIDGE MANUFACTURING IN HOUSE – INSTRUMENTS OUTSOURCED TO CONTRACT MANUFACTURER

**Cartridges**
- Experienced manufacturing and QC teams
- ISO 13485:2016 certified and FDA-inspected (Q1/2019)
- Dedicated 1,600 m² facility for cartridge manufacturing
  - Two ISO-8 and one ISO-7 clean-rooms
  - Three QC laboratories
  - Scalable capacity

**Instruments**
- Unyvero Systems manufactured by Zollner Elektronik (Top-tier EMS Provider)

- Hundreds of thousands cartridges manufactured to date
- Scalable operational capacity currently estimated at up to 1 million cartridges (based on 24/7 processing) annually
- Seamless supply chain management
OUTLOOK: GEOGRAPHIC EXPANSION
UNYVERO LRT – CUTTING-EDGE MDx FOR THE U.S.

OFFERING UNIQUE ADVANTAGES FOR SEVERE BACTERIAL PNEUMONIA

- Most comprehensive panel specifically tailored to bacterial pneumonia delivering unique clinically actionable insights
- Sample-to-answer direct from native specimen
- Broadest coverage of carbapenem resistance
- Only molecular pneumonia panel to cover penicillin resistance

Multiple strong clinical data sets presented at ASM 2019
INITIAL FOCUS ON HOSPITALS AND LTAC* MARKETS:

- Initially targeting about 1,000 Tier 1 and Tier 2 hospitals based on # of ICU beds and high incidence of pneumonia in each of the Territory Sales Manager territories
- Explore and qualify LTAC facilities associated with large hospital networks
- Seek early adopters that embrace rapid results over current methodology and that may not require extensive patient outcome study support
- Target hospitals with strong antibiotic stewardship programs that may gravitate to 2016 IDSA VAP/HAP guidelines

*LTAC = Long term acute care
U.S. COMMERCIALIZATION

STRONG FUNNEL OF COMMERCIAL OPPORTUNITIES FOR UNYVERO LRT DESPITE SMALLER COMMERCIAL FOOTPRINT

> Built solid funnel of sales opportunities since launch
> Focus on early-adopter accounts as a consequence of small size of U.S. commercial operation
> As of mid year 17 Unyvero A50 Analyzers installed with numerous commercial evaluations ongoing – first evaluations nearing completion
> Multiple near-term opportunities for additional evaluations
PLANNED U.S. UNYVERO PORTFOLIO EXPANSION

SUBMITTED UNYVERO LRT FDA FILING FOR BAL SAMPLES IN JULY 2019

LRT for Use with BAL Samples
> LRT optimized for use with bronchoalveolar lavage (BAL) samples
> Successfully completed clinical validation trial with 90.1% (94.7%) sensitivity at 98.4% (97.9%) specificity in prospective (retrospective) cohorts
> Significant performance improvement in sensitivity compared to 2016 FDA trial
> FDA submission in July – interactive review based on FDA AI letter ongoing

IJI Invasive Joint Infection Cartridge
> Potential next Application Cartridge for the U.S. market
> Synovial fluid sample collection ongoing at multiple sites in the U.S.
> Sample stability study completed at 3 trial sites with additional collection ongoing
> Further development subject to funding and/or partnering
GEOGRAPHIC EXPANSION: CURETIS IN CHINA

CHINA REPRESENTS A STRONG POTENTIAL GROWTH MARKET FOR CURETIS

Distribution Agreement with Beijing Clear Biotech (BCB)

> Covers China, Taiwan, and Hong Kong (via Technomed)
> BCB will conduct and fully fund all clinical trials for NMPA approval
> BCB committed to minimum purchase of Unyvero Systems (360) and Application Cartridges (1.5 Mio) over 8 year period from NMPA approval

> Revenue potential implied would be > EUR 30 mio p.a. in years 6 to 8 on top of the > 60 Mio EUR cumulative revenue in years 1 to 5

UPDATE ON CHINA

> Submitted for approval of Unyvero Instrument and Unyvero HPN Cartridge based on US-FDA and EU CE-IVD clinical study data in February 2019
> NMPA hosted expert panel meeting that discussed Unyvero HPN submission in July 2019 – final minutes pending
> Expect possible NMPA approval and subsequent commercial impact from 2020 onwards
MEDIUM TERM UPSIDE POTENTIAL THROUGH PRODUCT PORTFOLIO DEVELOPMENT
EXPANSION TO LOW- AND MID-PLEX APPLICATIONS & ATTRACTIVE PARTNERING OPPORTUNITY

UNYVERO A30 RQ: SMALL, FAST, QUANTITATIVE

A30 RQ: Key Design Features*

- Low- to Mid-plex with 5-30 targets
- Sensitive and quantitative real-time PCR technology
- Processes any native samples leveraging Unyvero Lysator when required
- Rapid 45-90 min time-to-result
- Easy to use with 2-5 min hands-on time
- Small footprint
- Point-of-care capable
- Low COGS Target: >66% reduction vs. current high-plex Unyvero (Instrument & Consumables) at scale
- Modular concept for full integration with other Unyvero modules or stand-alone operation

* in development, latest design concept; final product may differ.
UNYVERO A30  **RQ: R&D PROGRESSING TOWARDS PARTNERING**

**TARGET DEVELOPMENT COMPLETION OF FULLY INTEGRATED PLATFORM IN H1-2020**

**Current Development Status**
- First multiplex PCR successfully demonstrated on fully functional prototypes in tech due diligence for potential partners
- Manufacturing aspects fully specified and in development or implementation phase
- Expect to progress development in H2-2019 and H1-2020 for full V&V readiness for licensing partner’s assays

**Status of Partnering Discussions**
- Curetis is actively engaged in several potential partnering and licensing discussions. Deal closing will likely depend on finalizing instrument and cartridge development over the coming quarters subject to successful financing to fund such final development steps.
ARES GENETICS TECHNOLOGY PLATFORM

DATA INTELLIGENCE FOR NEXT-GEN MOLECULAR MICROBIOLOGY

ARESdb & ARES Technology Platform

> Likely the world’s most comprehensive database on the genetics of AMR covering > 30 years of emerging antibiotic resistance
> Advanced bioinformatics and artificial intelligence solutions to inform infectious diagnostics and therapeutics covered by a broad IP portfolio
> Collaboration-based business model to fast-track digital AMR solutions – validated through partnerships with Sandoz, Qiagen, and global IVD and NGS companies
> Launch of unique next-generation NGS services by ARESlab Vienna for molecular microbiology in Q3-2019

AI-powered AMR Knowledgebase & Decision Support

© 2019 Curetis N.V.
ARES GENETICS BUSINESS EXECUTION

FAST-TRACK TO ESTABLISHING A NGS-BASED MOLECULAR MICROBIOLOGY FRANCHISE

- R&D initiation by Ares Mgmt Team at SIEMENS
- “The Digital Microbe” R&D Grant (~ €1.6 M)
- “AI-powered NGS” R&D Grant (~ €1.3 M)
- Grant of Key Patent on Genetic Testing
- Recognized as Top 30 AI Start-up by Forbes

© 2019 Curetis N.V.
ARES GENETICS’ PARTNER ECO SYSTEM

BUILDING A LEADING NEXT-GEN MOLECULAR MICROBIOLOGY FRANCHISE WITH GLOBAL PLAYERS

Strategic Collaboration with global NGS Leader

Strategic Collaboration with global Pharma Leader

Strategic Collaboration with global Bioinformatics Leader

Globally Leading IVD Company

~ € 3 Mio total project volume of co-funded R&D projects

IVD Partnership expanded following successful feasibility study

Initial Technology Development by Mgmt Team

© 2019 Curetis N.V.
## WHY CURETIS? STRATEGIC OPTIONALITY WITH OPGEN!

**LEADER IN MOLECULAR MICROBIOLOGY WITH MULTIPLE PLATFORMS, PRODUCTS, AND DIFFERENTIATED CONTENT AND MANY ATTRACTIVE PARTNERING OPPORTUNITIES**

<table>
<thead>
<tr>
<th><strong>Combining Business with OpGen:</strong></th>
<th>Establish a world-leading antimicrobial resistance (AMR) precision medicine business</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Versatile Unyvero MDx Platform:</strong></td>
<td>Sample-to-Answer MDx allowing broad range of applications: from 5+ target triage-screen, via 10 to 30 target rapid tests to 100+ target syndromic panels</td>
</tr>
<tr>
<td><strong>Validated Products in an Attractive Market:</strong></td>
<td>Unique Unyvero System and Applications address high unmet needs in some of the most prevalent infectious disease indications in hospitalized patients</td>
</tr>
<tr>
<td><strong>Unique U.S. Application:</strong></td>
<td>Unyvero LRT, first ever pneumonia MDx panel cleared by U.S. FDA with anticipated clearance also for broader sample range in the coming months</td>
</tr>
<tr>
<td><strong>Next Generation Molecular Microbiology:</strong></td>
<td>Growing business with unique data-driven, NGS-based solutions for pharma and diagnostics by Ares Genetics</td>
</tr>
<tr>
<td><strong>Strong Technology Base:</strong></td>
<td>Broad patent portfolio covering key aspects of sample preparation, nucleic acid amplification and detection, and molecular microbiology content</td>
</tr>
<tr>
<td><strong>Multiple strategic partners and attractive Partnering Opportunities:</strong></td>
<td>Further near-, mid- and long-term partnering opportunities beyond the core business in the rapidly growing market for PCR and NGS-based Molecular Microbiology</td>
</tr>
</tbody>
</table>
STRONG MANAGEMENT BOARD

COMBINES DECADES OF OPERATIONAL AND COMMERCIAL EXPERIENCE

Oliver Schacht, Ph.D.
CEO Curetis N.V.
~20 years in MDx and biotech (ex CFO Epigenomics AG and CEO Epigenomics, Inc.)

Dr. Achim Plum,
CBO Curetis N.V. & Managing Director Ares Genetics GmbH
~20 years in commercial roles in IVD/MDx, Biotech & Pharma (ex Siemens, Epigenomics, Schering)

Johannes Bacher,
COO Curetis N.V. & Co-Founder Curetis
~20 years R&D and management experience (ex Hewlett Packard, Agilent Technologies, Philips)
SUPERVISORY BOARD

EXPERIENCED AND DIVERSE NON-EXECUTIVE SUPERVISORY BOARD

William E. Rhodes, III
Chairman of the Board;
Chairman of Remuneration Committee;
ex Becton Dickinson, USA

Mario Crovetto
Chairman of the Audit Committee;
ex CFO Eurand / Recordati,
Italy

Dr. Rudy Dekeyser
Member of the Board;
LSP,
Belgium

Dr. Werner Schäfer
Vice chairman;
Chairman of Nomination & Appointment Committee;
ex COO Roche Diagnostics,
Germany

Prabhavathi Fernandes, Ph.D.
Member of the Board;
ex CEO of Cempra Pharmaceuticals Inc.,
Bristol-Myers Squibb Pharmaceutical Research Institute,
Abbott Laboratories,
USA

Dr. Nils Clausnitzer
Member of the Board;
ex VWR International LLC / VWR GmbH
ex QIAGEN, Olympus, Abbott
Germany
CURETIS OVERVIEW

KEY FACTS AT A GLANCE

- Listed on Euronext Amsterdam and Brussels
- Ticker symbol: CURE
- IPO: 11th Nov 2015
- No. of shares outstanding: 24,933,474*
- Current market capitalization: approx. €9.2 million**
- Share ownership >3% as of 30 Sep 2019

Research Analyst Coverage

<table>
<thead>
<tr>
<th>Analyst</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Redhead</td>
<td>goetzpartners</td>
<td>London, U.K.</td>
</tr>
</tbody>
</table>

* As of 30 Sep 2019
** Source: Euronext as of 30 Sep 2019

© 2019 Curetis N.V.
## KEY FIGURES H1-2019 (UNAUDITED)

<table>
<thead>
<tr>
<th>Key Figures H1-2019 (unaudited)</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the first 6 months ended 30 June</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global Installed Base as of 30 June (Analyzers)</td>
<td>162</td>
<td>170</td>
</tr>
<tr>
<td>Revenue (in thousand EUR)</td>
<td>807</td>
<td>1,088</td>
</tr>
<tr>
<td>Net cash and cash equivalent at the end of the period (in thousand EUR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Net cash &amp; cash equivalents at the beginning of the year</td>
<td>16,311</td>
<td>10,279</td>
</tr>
<tr>
<td>- Net decrease in cash &amp; cash equivalents</td>
<td>-4,739</td>
<td>-2,486</td>
</tr>
<tr>
<td>- Effects of exchange rate changes of cash &amp; cash equivalents</td>
<td>74</td>
<td>16</td>
</tr>
</tbody>
</table>

### 2019 Financial Calendar

<table>
<thead>
<tr>
<th>Report/Event</th>
<th>Release Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 2019</td>
<td>14 Nov 2019</td>
</tr>
</tbody>
</table>

Full 2019 FIRST SIX MONTHS BUSINESS AND FINANCIAL UPDATE: [https://curetis.com/investors/#financial-reports](https://curetis.com/investors/#financial-reports)